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Aim: This study aimed at investigating factors associated to late rectal and bladder toxicity
following radiation therapy and the effectiveness of Hyperbaric Oxygen Therapy (HBOT)
when toxicity is grade ≥2.
Background: Radiation is frequently used for prostate cancer, but a 5–20% incidence of late
radiation proctitis and cystitis exists. Some clinical and dosimetric factors have been deﬁned
without a full agreement. For patients diagnosed of late chronic proctitis and/or cystitis grade
≥2  treatment is not well deﬁned. Hyperbaric Oxygen Therapy (HBOT) has been used, but its
effectiveness is not well known.
Materials and methods: 257 patients were treated with radiation therapy for prostate can-
cer. Clinical, pharmacological and dosimetric parameters were collected. Patients having a
grade ≥2 toxicity were treated with HBOT. Results of the intervention were measured by
monitoring toxicity by Common Toxicity Criteria v3 (CTCv3).
Results: Late rectal toxicity was related to the volume irradiated, i.e. V50 > 53.64 (p = 0.013);
V60  > 38.59% (p = 0.005); V65 > 31.09% (p = 0.002) and V70 > 22.81% (p = 0.012). We  could not
correlate the volume for bladder. A total of 24 (9.3%) patients experienced a grade ≥2. Only
the  use of dicumarinic treatment was signiﬁcant for late rectal toxicity (p = 0.014). A total of
14  patients needed HBOT. Final percentage of patients with a persistent toxicity grade ≥2
was 4.5%.Conclusion: Rectal volume irradiated and dicumarinic treatment were associated to late rec-
tal/bladder toxicity. When toxicity grade ≥2 is diagnosed, HBOT signiﬁcantly ameliorate
symptoms.©  2013 Greater Poland C
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.  Background
adiation therapy is a well established treatment for prostate
ancer in organ-conﬁned disease, including early and locally
dvanced cases and post-operatively when appropriate.1,2
uring recent decades, doses delivered to the prostate
land and seminal vesicles have been increased due to
tudies demonstrating that better disease control can be
btained through radiation dose escalation. Although present
elivering techniques using three dimensional conformal
adiotherapy (3CRT) or intensity modulated radiotherapy
IMRT) have signiﬁcantly reduced doses to surrounding nor-
al  tissues, concern still exists regarding late toxic effects on
he bladder and rectum.3–6 Previously published reports on
ate toxicity in relation to 3D-CRT for prostate cancer show
n incidence of between 5% and 20% of patients.7,8
Some factors have been previously described in rela-
ion to late rectal and/or bladder toxicity, including clinical,
harmacological and dosimetric factors. However, a general
onsensus does not exist among the various reports.9–12
It is rare for severe late rectal and/or bladder toxic-
ty following radiation to be diagnosed, whereas toxicities
igher than grade >2 (CTCv3) are more  frequently observed
ue to their being very detrimental to daily activities and
uality of life. Various different interventions have been
ested to determine whether they improve or ameliorate
ymptoms deriving from chronic rectitis, particularly rec-
al bleeding, including corticosteroids or sucralfate topic
pplications and cautery or argon therapy, but with unclear
eneﬁts.13,14
For years, Hyperbaric Oxygen Therapy (HBOT) has been
escribed as an effective option for late rectal and bladder
oxicity, but most reports are retrospective and indicated for
atients failing in other interventions. Another limitation
f these studies is that they have analyzed heterogeneous
roups with a wide range of primary tumors and radiation
echniques.15–18 To the best of our knowledge, only one multi-
entre randomized trial has been published comparing HBOT
ith placebo for chronic and refractory radiation proctitis. In
aid study, however, most patients were treated for gynecolog-
cal tumors, including external radiotherapy and some forms
f brachytherapy.14 A study reporting a signiﬁcant improve-
ent in symptom control and quality of life has been recently
eported.18
In order to provide further insight into factors inﬂuenc-
ng late pelvic toxicity following radiation i.e. proctitis and/or
ystitis, we  conducted a study on a cohort of consecutive
atients treated uniformly with conformal radiation ther-
py (3D-CRT) for prostate cancer. Our aims were to describe
he inﬂuence of clinical and dosimetric factors as predic-
ors for late pelvic toxicity of patients treated with 3DCRT
or prostate cancer. We  also report the incidence of toxicities
nd ﬁnal results after treating with HBOT patients having a
rade >2..1.  Aim  of  the  study
he aim of the study is to ﬁnd clinical and dosimetric predic-
ive factors for late rectal/bladder toxicity for prostate cancertherapy 1 8 ( 2 0 1 3 ) 298–303 299
patients treated using three dimensional conformal radiothe-
rapy and to measure the ﬁnal toxicity reduction after using
hyperbaric oxygen therapy on patients experiencing a toxicity
grade ≥2.
2.  Materials  and  methods
We  included patients treated radically or post-operatively at
the Catalan Institute of Oncology’s Radiation Oncology Service
in Girona (ICO-Gi) with 3D-CRT for prostate cancer.
Inclusion criteria were: histological diagnosis of prostate
cancer, clinical stage from T1 to T4, radical radiation ther-
apy and post-operative or adjuvant therapy using 3D-CRT. A
minimum follow-up of 6 months was required.
Late radiation proctitis or cistitis was classiﬁed according
to CTCv3 and was considered only when started 6 months or
later after the completion of 3D-CRT.13
Radiation therapy was administered at a single institution
(ICO-Gi) using 3D-CRT with 18Mv photon equipment (CLINAC
2100-Varian®). Typical dose prescription was 50 Gy to 95% of
the Planned Target Volume (PTV1) encompassing the prostate
gland and seminal vesicles with a 7–10 mm margin. When
clinically admissible, posterior margin was limited to 5 mm.  A
boost of 26 Gy was delivered after excluding seminal vesicles
(PTV11) from the PTV1. In cases of seminal vesicle involve-
ment, demonstrated either by MRI  or surgery (T3b/pT3b), PTVs
were designed accordingly in order to provide sufﬁcient cov-
erage of the disease.
Patients treated post-operatively received a dose of
70–72 Gy to 95% of PTV1 and treatment volumes according to
international guidelines.1,20
Normal tissue constraints for rectum were V50 < 65%
and V70 < 20%; and for bladder V60 < 40%. Doses to femoral
heads were limited to 50 Gy whenever possible. Dose dis-
tribution, doses to rectum and bladder and Dose Volume
Histograms (DVH) were calculated using the Eclipse software
v 7.5(Varian®).
Baseline study protocol included the following factors
regarding clinical, surgical and pharmacological history:
cTNM and pTNM when appropriate, Gleason score, diagnostic
PSA level (ng/mL). Co-morbid conditions, i.e., diabetes, hyper-
tension, collagen diseases, abdominal surgery, arteriopathy,
inﬂammatory bowel disease, benign anal pathology, smoking
habit, anticoagulants, antiaggregants, androgen deprivation
and chemotherapy treatments.
Dosimetric parameters recorded for rectum were: maxi-
mum doses (Dmax); V50, V60, V65 and V70; for bladder: Dmax,
V40, V50 and V60.
Follow-up was based on regular visits every 3 months dur-
ing the ﬁrst 2 years, every 6 months until 5 complete years
and annually thereafter. Toxicities for proctitis and cystitis
according to CTCv3 were recorded at every visit.13
In patients diagnosed of proctitis and/or cystitis grade ≥2,
a colonoscopy, cystoscopy or both were performed to con-
ﬁrm diagnoses and exclude other etiologies. Finally, patients
considered to be candidates, were referred to the Unit of
Hyperbaric Medicine at Palamós Hospital, Girona (Spain) for
Hyperbaric Oxygen Therapy (HBOT).
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2.1.  Statistical  analysis
For the statistical analysis, the groups of variables deﬁned as
tumor characteristics, co-morbid conditions and pharmaco-
logical history were treated as categorical (usually dichotomy:
yes/no). Age and radiation doses were analyzed as continuous.
Radiation toxicity according to the CTCv3 grading system
was re-codiﬁed as a dichotomous scale (yes/no), code “yes”
included grades 1–4.
In order to study a possible correlation between toxicity
and categorical variables, a bi-variant descriptive model using
contingence tables was used. We applied Chi-square tests and
exact Fischer’s statistics. Where there was a statistically sig-
niﬁcant association, we  calculated the odds ratio.
All statistical calculations were done using the SPSS soft-
ware  version 18.
3.  Results
From 1st June 2007 to 30th June 2010, a total of 278 patients
were treated with radiation therapy for prostate cancer, 257
of them met  the inclusion criteria, 21 were excluded because
they received a combination of external radiotherapy and high
dose rate brachytherapy or were missed of follow-up.
Age was 70 ± 6.14 years (range 52–82 years).
Tumor characteristics are shown in Table 1. In short, most
frequent T stage was T2a/b (25%), Gleason 7 was assigned
to almost half of the patients (48.2%) and pre-treatment PSA
<10 ng/mL was the most frequent, measured in 45.5% of cases.
Radiation therapy was prescribed as radical treatment in
216 (84%) cases and post-operatively in 41 (16%).
Doses to the rectum for the whole group were: Dmax:
76.02 ± 1.99 Gy (range 77.95–71.40 Gy), V50 Gy(%): 53.47 ± 12.72
(range 79.86–33) and V70 Gy(%): 21.82 ± 10.42 (range 43–4).
Doses to the bladder were: Dmax 75.88 ± 1.97 Gy (range
78.27–71.4 Gy), V60 Gy(%): 42.57 ± 17.69 (range 68–12).Follow-up time calculated from the end of radiotherapy to
the last visit was 38.9 ± 9.6 months (range 9.50–58.6 months;
median 39.6 months). During the follow-up, 15 patients died
Table 1 – Tumor characteristics.
Patients %
cTNM
T1-T1c 62 24.1
T2a I b 64 24.9
T2c 54 21.0
T3a 52 20.2
T3b I c 20 7.8
T4 1 0.4
TX 4 1.6
Gleason
<7 77 30
7 124 48.2
>7 47 18.3
Unknown 9 3.5
PSA (ng/mL)
<10 117 45.5
10–20 91 35.4
>20 46 17.9
Unknown 3 1.1iotherapy 1 8 ( 2 0 1 3 ) 298–303
and 5 were lost. However, all but one who died 9 months after
treatment was followed for a minimum time of 12 months.
Incidence of rectal toxicity according to CTCv3 was: no
toxicity, 203 (78.99%); Grade 1, 30 (11.7%); Grade 2, 24 (9.3%).
Incidence of bladder toxicity was: no toxicity, 206 (80.15%);
Grade 1, 31 (12.1%); Grade 2, 20 (7.8%). Only 7 (2.7%) had toxicity
Grade 2 in both locations.
After treating the group of patients presenting late rectal
or bladder bleeding with HBOT, overall grade 2 toxicity was
reduced to 4.5%.
3.1.  Clinical/dosimetric  factors  and  late  toxicities
Univariate analyses showed that factors associated with
late rectal toxicity were older age, comparing <65 years
vs. 65–74 years vs. >74 years (p = 0.042), treatment with
acenocumarol (p = 0.014) and radical radiotherapy vs. post-
operative/adjuvant (p = 0.018). In the case of bladder toxicity,
none of the analyzed factors showed statistical signiﬁcance.
After analyzing statistically signiﬁcant factors in a multi-
variate model, none of them retained statistical signiﬁcance
(Table 2).
Average doses as measured on dose–volume histograms
(Dmax, V50, V60, V65 and V70) for rectal toxicity were signiﬁ-
cantly higher in patients experiencing toxicity (p < 0.05), but
this signiﬁcance was not observed for the maximum dose
(Dmax). For bladder toxicity, we  could not demonstrate any sta-
tistical signiﬁcance between Dmax, V40, V50 and V60 and late
toxicity (Table 3).
During the follow-up, 15 (5.8%) patients had a biochemical
relapse, 5 (1.94%) had a loco-regional failure, 8 (3.11%) had dis-
tant metastasis and 15 (5.8%) died; 5(1.94%) were lost. However,
all patients were followed for at least 12 months.
The mean age of this sub group was 72 ± 3.38 years (range
65–78 years). Ten out of 24 patients diagnosed with grade
≥2 rectal toxicity did not receive HBOT because they did not
complain of active rectal bleeding. A total of 20 patients experi-
enced bladder toxicity but only 4 complained of hematuria; all
4 also had rectal bleeding. The ﬁnal number of patients treated
with HBOT was 14. Late rectal and bladder toxicity CTCv3 ≥2
for the whole group was 9.3%. After using up-front HBOT on
patients experiencing rectal or bladder bleeding 10 patients
remained unchanged (non-bleeder group) and only 1 of the
14 patients experiencing bleeding had persistent symptoms,
leaving a ﬁnal 4.28% of patients with any form of late pelvic
toxicity.
4.  Discussion
Radiation therapy is one of the most frequently prescribed
treatments for localized prostate cancer and, as most patients
are cured or have long survival times, late toxicity is an impor-
tant concern for radiation oncologists.
Previously published reports on late toxicity in relation to
3D-CRT for prostate cancer show an incidence of between 5%
and 20%. In our own group of patients, it was 9.3%, which we
consider to be within the range of previous papers.7
Despite the fact that radiation proctitis and/or cystitis
are not very frequent, when they do occur they are very
reports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) 298–303 301
Table 2 – Co-morbid conditions and concomitant treatments in relation to late rectal and bladder toxicity.
Co-morbid conditions Patients (%) Rectal tox. 0 vs. >0. Bladder tox. 0 vs. >0
Chi value p Chi value p
Diabetes 46 (17.9) 0.020 0.886 0.195 0.659
Hypertension 102 (39.7) 0.243 0.622 0.486 0.490
Collagens diseases 3 (1.2) 0.006 0.937 0 0.993
Abdominal surgery a 107 (41.6) 2.471 0.480 1.829 0.609
Arteriopathy b 33 (12.8) 0.278 0.598 0.027 0.868
Inﬂammatory bowel disease 2 (0.8) 0.948 0.330 0.507 0.477
Benign anal pathology 21 (8.2) 0.077 0.781 0.445 0.505
Smoking habit
Active smoking 60 (23.3) 0.054 0.82 0.012 0.913
Pharmacological treatments
Anticoagulantsc 19 (7.4) 6.099 0.014 0.123 0.726
Antiaggregantsd 35 (13.6) 0.049 0.824 0.789 0.374
Androgen deprivation e 170 (66.1) 0.235 0.628 1.176 0.278
Chemotherapy 1 (0.4) 0.271 0.603  0.252 0.616
a Abdominal surgery includes intra and extra-peritonial surgery.
b Included ischemic heart disease.
c Includes acenocumarol treatment.
d Includes aspirin and clopidogrel.
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te Includes bicalutamide and/or LH-RH analogs.
etrimental to quality of life and normal daily activities. Many
ifferent factors have been studied to identify which patients
ave a higher risk of late radiation proctitis. In our study,
e  selected those factors we  considered most reproducible
nd measurable, including clinical, pharmacological and dosi-
etric parameters. Herold et al.,21 suggested an increasing
ncidence of late rectitis in diabetic patients and Fiorino
t al.,11 reported that previous abdominal surgery correlates to
ate rectal syndrome. Other factors, such as age and previous
no-rectal dysfunction, have also been suggested.22,23 In our
tudy, we  were unable to demonstrate a correlation between
o-morbidity and late toxicity; this is most probably due to the
mall number of patients. However, co-morbid conditions are
ot uniformly recorded from one study to another; a bias can
e suspected in previous published papers and probably our
wn work too.
Treatment by androgen deprivation has also been stud-
ed in relation to late pelvic radiation toxicity, but without
omogeneous results. Zelefsky et al. and Takeda et al.7,24
ailed to ﬁnd a correlation between androgen deprivation
nd late pelvic toxicity, which is consistent with our own
esults. However, other published reports demonstrated an
ncreasing risk of late genito-urinary toxicity in patients
n androgen deprivation.10,12,25 One possible explanation is
hat 15–43% of patients were on androgen deprivation in
Table 3 – Rectal/bladder toxicity according to irradiated volume
CTCv3 rectum = 0 CTCv3 rectum > 0 p 
Dmax 76.24 ± 2.25 76.59 ± 2.41 0.342 
V40 – – – 
V50 49.07 ± 13.52 53.64 ± 11.23 0.013 
V60 34.15 ± 10.52 38.59 ± 8.89 0.005 
V65 26.66 ± 9.19 31.09 ± 8.88 0.002 
V70 19.65 ± 8.42 22.81 ± 7.85 0.012 previous reports,7,10 whereas the percentage for our group
was 66.1%. The underlying mechanism behind the process
remains largely unclear, however, an impairment of the repar-
ative process after radiation injury induced by androgen
deprivation has been hypothesized.25
We  were only able to demonstrate an association between
anticoagulant treatment and late rectal bleeding, which has
also been shown by other authors.12,25
Dose/volume histograms provide much better reproducible
results for late rectal toxicity. In our study, a clear relation-
ship exists between higher values of V50, V60, V65 and V70
and an increasing rate of rectal late toxicity, demonstrating
that irradiated volume of the rectum plays an important role
in toxicity, a ﬁnding consistent with previous reports.9–11 Our
measured bladder toxicity did not show any correlation for
dose/volume parameters.
HBOT was ﬁrst described for treating late radiation procti-
tis in 1991.26 It was later used in the treatment of late pelvic
toxicities following radiation and reported to improve clini-
cal symptoms with a grade 3 group. Mayer et al.27 reported
a series of 18 patients treated for radiation proctitis and/or
cystitis. Most patients in their group had very long-lasting
toxicities and despite some very good results, with only 2
patients not responding, they suggested that earlier treatment
could provide a better improvement. Similarly, Jones et al.28
s.
CTCv3 bladder = 0 CTCv3 bladder > 0 p
76.26 ± 2.17 76.27 ± 2.41 0.988
46.31 ± 17.31 44.00 ± 16.48 0.380
37.48 ± 14.74 35.65 ± 14.07 0.414
28.16 ± 12.28 28.16 ± 12.28 0.397
– – –
– – –
d rad
r
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treated 10 patients experiencing radiation proctitis refractory
to medical or laser therapy with 8 responses and 2 failing. Both
authors included patients with toxicities graded 3 or 4 and
HBOT was offered 20 or more  months after the end of radio-
therapy. We decided to treat patients with HBOT as soon as
toxicity grade 2 (CTCv3) was diagnosed and results are there-
fore difﬁcult to compare, but we  had better response rates to
HBOT, with only one patient out of 14 failing.
After using HBOT an important improvement in symptom
control and quality of life could be observed, as previously
reported.19
In summary, we  demonstrated a correlation between anti-
coagulant treatment, rectal dose and late rectal toxicity.
When toxicity was grade 2 or more,  the use of HBOT led
an important ﬁnal treatment toxicity reduction. Finally, it is
worth highlighting that late gastrointestinal complications
of pelvic radiotherapy are present in about 5–20% of long
term survivors, which leads to gastrointestinal symptoms
affecting quality of life. The most appropriate care for these
patients is yet to be found, which opens an important ﬁeld of
research.
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